Table of Contents

    Topic review

    Oxadiazole

    View times: 65
    Submitted by: Valentina Pirota

    Definition

    Nowadays, an increasing number of heterocyclic-based drugs found application in medicinal chemistry and, in particular, as anticancer agents. In this context, oxadiazoles—five-membered aromatic rings—emerged for their interesting biological properties

    1. Introduction

    Oxadiazoles are small five-membered heterocycles, composed of two carbon, one oxygen, and two nitrogen atoms, which attracted a lot of interest in different scientific disciplines: from medicine [1][2] and agrochemistry [3] to materials science [4][5].

    Their aromatic flat surface is effective in the target binding, through π-stacking interactions, or to properly outdistance the substituents according to a specific orientation [6]. Depending on nitrogen atoms position, oxadiazoles exist in four different regioisomeric forms (Figure 1): 1,2,3-, 1,2,4-, 1,2,5-, and 1,3,4-oxadiazoles.

    Figure 1. Chemical structures of the four isomers of the oxadiazole.

    Among the four isomers, 1,2,4- and 1,3,4-oxadiazoles frequently occur in a large series of drug-like molecules [7], including antiviral [2][8], antihypertensive [9], anti-diabetic [10], anti-inflammatory, and analgesic [11], as well as anticancer compounds [12][13]. Probably, this is a direct consequence of the orientation of the side chains (-R1 and -R2 in Figure 1), very similar for 1,2,4- and 1,3,4-oxadiazoles with respect to 1,2,3- and 1,2,5-oxadiazoles. Indeed, small bioactive molecules with resembling shapes usually show target-binding similarity that translates into the same biological effects [14]. Moreover, their bioisosteric correspondence with ester and amide groups makes oxadiazoles an interesting synthetic alternative to avoid intrinsic molecular instability (e.g., due to hydrolysis reactions), guaranteeing different hydrogen-bonding potentials with the receptors [7].

    The extensively use of this class of heterocyclic compounds in medicinal chemistry is confirmed by the presence of several commercially available drugs based on these interesting scaffolds. The reasons for their success lie in an efficient and simple synthesis, high versatility, giving rise to elevated structural diversity, and remarkable stability, a key feature for in vivo applications. Thanks to its structural nature, oxadiazoles easily interact with bio-targets establishing π-stacking interactions or forming strong hydrogen bonds.

    During the last decades, the design of new oxadiazole-based scaffolds accelerated in medicinal chemistry, bringing most of these compounds to the preclinical stage or, even, to commercialization. Among these, the most commercially available drugs are Oxolamine, a cough suppressant [15], Ataluren, indicated for the treatment of Duchenne muscular dystrophy [16] and cystic fibrosis [17], Butalamine, a vasodilator, Proxazole, a drug for functional gastrointestinal disorders, Fasiplon, an anxiolytic drug [18], Raltegravir, an antiretroviral drug used to treat HIV [19], which has been recently proposed as repurposing drug against SARS-COV-2 [20], as well as the antiviral Pleconaril selected for the SARS-COV-2 spike protein [21] (Figure 2). Equally well known is Zibotentan, an anticancer drug in late-stage clinical trials (www.ClinicalTrials.gov Identifier: NCT00554229), which is a candidate in development by AstraZeneca (Figure 2).

    Figure 2. Structures of some of the most famous ligands bearing oxadiazole moiety.

    Considering the meaningful social impact of cancer, due to the incessant raise incidence, with resistance towards existing drugs and severe side effects, the need to develop novel anticancer drugs is compelling.

    Recently, it has been demonstrated that oxadiazoles can interact with specific targets, as demonstrated for enzymes, globular proteins and DNA structures. This correspondence helped to clarify the origin of cytotoxicity of these compounds, allowing the improvement of drug design in relationship with the identified target.

    It should be underlined that oxadiazoles that present relevant cytotoxicity are characterized by some common structural features: they present modification with bioactive compounds, an extended aromatic surface, or the presence of a sulphur-based functional group. These results evidence the important progresses achieved in the last few years, however, a lot of effort should be dedicatedto further optimize these chemical structures in order to enhance their potency and to improve the selectivity towards specific targets.

    2. Oxadiazoles Derivatives as Anticancer Agents without a Specific Target Identified

    A broad number of oxadiazole ligands with promising anticancer activity have been developed despite their mechanism of action must be still clarified. In this sense, modification of oxadiazole scaffolds through conjugation to bioactive natural products represents a very promising approach. Mironov et al. exploited Furano-diterpenoids of the labdane series, an anti-inflammatory and anti-allergic drug-like [22], to build novel and potent derivatives [23]. In detail, 1,2,4-oxadiazoles were conjugated to labda-8(9),13,15-triene or labda-8(17),13,15-triene core and their antiproliferative activity and GI50 on CEM-13, MT-4 and U937 cells were measured [23]. From this screening, compound 55 (Figure 3) emerged for its remarkable toxicity, with GI50 values of 0.08 ± 0.03 µM on CEM-13, and 0.35 ± 0.11 µM on MT-4. Moreover, cytofluorimetric analysis demonstrated that treatment of U937 cells with 55 induced apoptosis in 46.8% of cells after 24 h and 84.4% after 48 h [23].

    Figure 3. Oxadiazoles conjugated to bioactive molecules.

    Each molecule has been screened at a single dose of 100 µM against a panel of 60 cancer cell lines. From this screening 57 (Figure 4), emerged as the most efficient antiproliferative agent, highlighting that an extended aromatic surface (two phenyl rings with electron-donating substituents) could guarantee better anticancer activity.

    Figure 4. Oxadiazoles with extended aromatic system.

    Following the same approach, Salahuddin and co-workers synthesized a library of 1,3,4-oxiadiazoles conjugated to quinolines and benzimidazole derivatives and measured their growth inhibition percentage (GP) towards a broad panel of cancer cell lines [24]. Compound 58 (Figure 4) emerged for its remarkable toxicity on HTC-116, with GP equal to 7.52 µM and GI50 of 1.41 µM. Therefore, the introduction of quinoline moiety resulted in a promising path for the development of new anticancer drugs.

    Conjugation to benzimidazole scaffold has been also exploited by Srinivas et al., obtaining compound 59 (Figure 4), highly toxic on A549 cells, with IC50 of 0.12 ± 0.01 µM [25].

    Modification of the 1,3,4-oxadiazole scaffold with only two phenyl rings resulted to be a successful strategy also for Mochona et al., that individuated compound 60 (Figure 4) as the best of the series with the highest toxicity in particular on PC-3 cells (IC50 = 0.22 µM) [26]. Subsequently, it has been verified that 60 induced apoptosis and cell cycle arrest at G0/G1 and S phases.

    Introduction of 2-substituted pyridines, as reported by Kumar et al., led to promising results as demonstrated by proving the efficiency of these compounds against HeLa, DU145, HepG2, and MDA-MB-231 cancer cell lines [27]. Among them, 61 (Figure 4) showed higher toxicity in particular on DU145 cells with an IC50 value of 10.7 µM. This enhanced activity has been attributed to both the presence of a trifluoromethyl group, that improves lipophilicity, and to the electron-donating effect of methoxy substituent [27].

    On the contrary, Cascioferro et al. extended the aromatic system of 1,2,4-oxadiazole exploiting indole and azaindole derivatives with different types of substituents, including halogen atoms and methoxy units [103]. After a preliminary screening on HCT-116 cells, compound 62 (Figure 4) emerged as the most potent, displaying high toxicity on different cell lines and specifically on MCF-7 cells with IC50 of 0.65 ± 0.05 µM. Furthermore, authors demonstrated that 62 caused cell cycle arrest (more than 60%) at G0/G1 phase and its ability to induce apoptosis was confirmed through Annexin V/PI dual staining method, followed by cytofluorimetric analysis [28].

    The presence of an aromatic system is not the only important structural feature: it has been discovered that also oxadiazoles conjugating to sulfur atoms present interesting biological properties. Guogang et al. obtained promising results after the synthesis of a library of 1,2,4-triazoles and 1,3,4-oxadiazoles, including a series of 5-thioxo-1,3,4-oxadiazole analogs, differing for the kind of phenyl substituent and the type of thio-derivative introduced on the lateral chain in position 5 [29]. Comparing 1,2,4-triazoles and 1,3,4-oxadiazole analogs, 1,2,4-triazoles have lower toxicity. Indeed, the highest antiproliferative activity was recorded by 65 (Figure 5) on K562 cells, showing an 85% inhibition ratio [29].

    Figure 5. Oxadiazoles containing sulfur-based functional groups.

    In an attempt to improve both bioavailability and the antitumor effects, Kumar et al. synthesized different 2,5-disubstituted-1,3,4-oxadiazoles, containing both sulfonamide moiety and fluorine atoms, to increase lipophilicity and cellular uptake [30]. Sulfonamide groups, present in several FDA-approved drugs, were often used to improve drug-like design [31][32]. In this context, 67 (Figure 5) stood out for a drastic reduction in cell survival percentage, which was below 30% in the case of K562 cells and 42.52% and 40.68% with Colo-205 and MDA-MB 231, respectively. This result suggests that the presence of electron-donating substituents on this kind of scaffold increased anti-cancer toxicity.

    Another interesting functional group involving sulfur atom is represented by dithiocarbamate, recently emerged for its promising anticancer properties [33]. With the aim to improve anticancer efficacy, Li et al. synthesized novel heteroarylmethylcarbamodithioates containing 1,3,4-oxadiazole scaffold, and evaluated their biological activity on hepatoma cells Bel-7402, breast cancer cells SK-BR-3 and MDA-MB-468 [34]. During this screening, compound 70 (Figure 5) resulted to be the most toxic with marked preference for Bel-7402 (IC50 = 1.23 ± 0.49 µM) and SK-BR-3 (IC50 = 0.58 ± 0.05 µM) cells. Due to its promising activity, 70 has been further tested against other cancer cell lines, including lung cancer (H1299, H460, H522), hepatoma (Bel-7402), breast (MDA-MB-468, SK-BR-3), colorectal (COLO205, HCT-8, HCT-116, SW620) and prostate (DU145, PC3) in comparison with non-malignant cell lines (LO2 and 293). 70 presented good toxicity in all cancerous cells, with IC50 values from 0.39 to 7.91 µM, while IC50 values above 9 µM were measured in normal cells. Moreover, 70 caused chromatin condensation, a clear sign of induced apoptosis, and stopped cell cycle at G2/M phase, both in Bel-7402 and PC-3 cells. Further analysis evidenced that this substrate has a mechanism of action similar to the well-known Taxol [35]; indeed, treatment with 70 increased levels of MPM-2 and phosphorylated histone H3, two specific mitotic molecular markers that indicate mitotic arrest. This was further confirmed by the generation of Supernumerary Centrosomes and Multipolar Spindles formation upon treatment with 70, an abnormal behavior observed also with Taxol, highlighting 70 as a promising candidate for the treatment of different kinds of tumors [34].

    As an alternative to previously reported approaches, modification with carbohydrates is a common strategy used to improve the activity of bioactive molecules and it has been exploited also in the case of 1,2,4-oxadiazoles. Avanzo et al. reported some 1,2,4-oxadiazoles conjugated to D-ribofuranoside [36] and tested their antiproliferative activity against A549, HBL-100, HeLa, SW1573, T-47D, and WiDr cancer cell lines. However, also these compounds presented only a moderate anticancer effect, with IC50 ranging from 4 µM to over 100 µM.

    Another interesting functionalization of 1,3,4-oxadiazoles scaffold is the conjugation of fatty acid analogs [37]. Hassan and co-workers described the synthesis of a library of 1,3,4-oxadiazol-2(3H)-one with fatty acids with different chain-lengths and numbers of double bonds, chosen for their promising anticancer properties [38]. Antiproliferative activity of each molecule has been tested against HeLa, MDA-MB-231, and KCL-22 (Lymphoblastoid) cells for 48 h. Authors measured IC50 values in the 6–50 µM range, with the highest toxicity observed in presence of 71 (IC50 = 6.3 ± 1.1 µM on HeLa cells; IC50 = 8.3 ± 1.2 µM on KCL-22; IC50 = 9.6 ± 1.2 µM on MDA-MB-231; Figure 6), characterized by a 16-carbon atoms chain covalently bound to 1,3,4-oxadiazol-2(3H)-one. This result underlined that the presence of a cis-double bond and a hydroxy group are two key structural features to guarantee more potent activity, despite the toxicity of 71 resulted to be lower compared to reference compound doxorubicin. Moreover, fluorescence microscopy micrographs, in agreement with previous experiments, showed that 71 was able to induce apoptosis with higher efficiency compared to other compounds of the library.

    Figure 6. Oxadiazole conjugated to long-chain fatty acid.

    In this context, several signs of progress were accomplished in the past years as confirmed by positive results described above. However, to develop novel and specific drug-like, a lot of effort is still required to identify other modifications and structural elements that could guarantee not only high antitumor potency but also interaction with specific and defined targets.

    The entry is from 10.3390/ijms21228692

    References

    1. Berger, J.; Li, M.; Berger, S.; Meilak, M.; Rientjes, J.; Currie, P.D. Effect of Ataluren on dystrophin mutations. J. Cell. Mol. Med. 2020, 24, 6680–6689.
    2. Caputo, F.; Corbetta, S.; Piccolo, O.; Vigo, D. Seeking for Selectivity and Efficiency: New Approaches in the Synthesis of Raltegravir. Org. Process Res. Dev. 2020, 24, 1149–1156.
    3. Khallaf, A.; Wang, P.; Liu, H.; Zhuo, S.; Zhu, H. 1,2,4-Oxadiazole ring–containing pyridylpyrazole-4-carboxamides: Synthesis and evaluation as novel insecticides of the anthranilic diamide family. J. Heterocycl. Chem. 2020, 57, 1981–1992.
    4. Fershtat, L.L.; Makhova, N.N. 1,2,5-Oxadiazole-Based High-Energy-Density Materials: Synthesis and Performance. ChemPlusChem 2020, 85, 13–42.
    5. Salassa, G.; Terenzi, A. Metal Complexes of Oxadiazole Ligands: An Overview. Int. J. Mol. Sci. 2019, 20, 3483.
    6. Boström, J.; Hogner, A.; Llinàs, A.; Wellner, E.; Plowright, A.T. Oxadiazoles in Medicinal Chemistry. J. Med. Chem. 2012, 55, 1817–1830.
    7. Biernacki, K.; Daśko, M.; Ciupak, O.; Kubiński, K.; Rachon, J.; Demkowicz, S. Novel 1,2,4-Oxadiazole Derivatives in Drug Discovery. Pharmaceuticals 2020, 13, 111.
    8. Tassinari, M.; Lena, A.; Butovskaya, E.; Pirota, V.; Nadai, M.; Freccero, M.; Doria, F.; Richter, S.N. A Fragment-Based Approach for the Development of G-Quadruplex Ligands: Role of the Amidoxime Moiety. Molecules 2018, 23, 1874.
    9. Zhu, W.; Bao, X.; Ren, H.; Liao, P.; Yan, Y.; Wang, L.; Chen, Z. Design, synthesis, and pharmacological evaluation of 5-oxo-1,2,4-oxadiazole derivatives as AT1 antagonists with antihypertension activities. Clin. Exp. Hypertens. 2016, 38, 435–442.
    10. Ibrahim, M.T.; Uzairu, A.; Shallangwa, G.A.; Ibrahim, A. In-silico studies of some oxadiazoles derivatives as anti-diabetic compounds. J. King Saud Univ.-Sci. 2020, 32, 423–432.
    11. Chawla, G.; Naaz, B.; Siddiqui, A.A. Exploring 1,3,4-Oxadiazole Scaffold for Anti-inflammatory and Analgesic Activities: A Review of Literature From 2005-2016. Mini Rev. Med. Chem. 2018, 18, 216–233.
    12. Bajaj, S.; Asati, V.; Singh, J.; Roy, P.P. 1,3,4-Oxadiazoles: An emerging scaffold to target growth factors, enzymes and kinases as anticancer agents. Eur. J. Med. Chem. 2015, 97, 124–141.
    13. Glomb, T.; Szymankiewicz, K.; Świątek, P. Anti-Cancer Activity of Derivatives of 1,3,4-Oxadiazole. Molecules 2018, 23, 3361.
    14. Boström, J.; Hogner, A.; Schmitt, S. Do Structurally Similar Ligands Bind in a Similar Fashion? J. Med. Chem. 2006, 49, 6716–6725.
    15. Ceyhan, B.B.; Karakurt, S. Effect of oxolamine on cough sensitivity in COPD patients. Respir. Med. 2002, 96, 61–63.
    16. Landfeldt, E.; Sejersen, T.; Tulinius, M. A mini-review and implementation model for using ataluren to treat nonsense mutation Duchenne muscular dystrophy. Acta Paediatr. 2019, 108, 224–230.
    17. Konstan, M.W.; VanDevanter, D.R.; Rowe, S.M.; Wilschanski, M.; Kerem, E.; Sermet-Gaudelus, I.; DiMango, E.; Melotti, P.; McIntosh, J.; De Boeck, K. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). J. Cyst. Fibros. 2020, 19, 595–601.
    18. Tully, W.R.; Gardner, C.R.; Gillespie, R.J.; Westwood, R. 2-(Oxadiazolyl)- and 2-(thiazolyl)imidazo[1,2-a]pyrimidines as agonists and inverse agonists at benzodiazepine receptors. J. Med. Chem. 1991, 34, 2060–2067.
    19. Cecchini, D.M.; Martinez, M.G.; Morganti, L.M.; Rodriguez, C.G. Antiretroviral Therapy Containing Raltegravir to Prevent Mother-to-Child Transmission of HIV in Infected Pregnant Women. Infect. Dis. Rep. 2017, 9, 7017.
    20. Toombs, J.M.; Van den Abbeele, K.; Democratis, J.; Merricks, R.; Mandal, A.K.J.; Missouris, C.G. COVID-19 in three people living with HIV in the United Kingdom. J. Med. Virol. 2020, 1–3.
    21. Calligari, P.; Bobone, S.; Ricci, G.; Bocedi, A. Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions with Antiviral Drugs. Viruses 2020, 12, 445.
    22. Chae, H.-S.; Chin, Y.-W. Anti-allergic effect of lambertianic acid from Thuja orientalis in mouse bone marrow-derived mast cells. Immunopharmacol. Immunotoxicol. 2012, 34, 250–255.
    23. Mironov , M.E.; Pokrovsky, M.A.; Kharitonov , Y.V.; Shakirov, M.M.; Pokrovsky, A.G.; Shults , E.E. Furanolabdanoid–based 1,2,4-oxadiazoles: Synthesis and cytotoxic activity. ChemistrySelect 2016, 1, 417–424.
    24. Salahuddinm; Mazumder, A.; Shaharyar, M. Synthesis, Characterization, and In Vitro Anticancer Evaluation of Novel 2,5-Disubstituted 1,3,4-Oxadiazole Analogue. Biomed Res. Int. 2014, 2014, 491492.
    25. Srinivas, M.; Satyaveni, S.; Ram, B. Synthesis and Anticancer Activity of 1,2,4-Oxadiazol Linked Benzimidazole Derivatives. Russ. J. Gen. Chem. 2018, 88, 2653–2657.
    26. Mochona, B.; Qi, X.; Euynni, S.; Sikazwi, D.; Mateeva, N.; Soliman, K.F. Design and evaluation of novel oxadiazole derivatives as potential prostate cancer agents. Bioorganic Med. Chem. Lett. 2016, 26, 2847–2851.
    27. Naresh Kumar, R.; Poornachandra, Y.; Nagender, P.; Santhosh Kumar, G.; Krishna Swaroop, D.; Ganesh Kumar, C.; Narsaiah, B. Synthesis of novel nicotinohydrazide and (1,3,4-oxadiazol-2-yl)-6-(trifluoromethyl)pyridine derivatives as potential anticancer agents. Bioorganic Med. Chem. Lett. 2016, 26, 4829–4831.
    28. Cascioferro, S.; Attanzio, A.; Di Sarno, V.; Musella, S.; Tesoriere, L.; Cirrincione, G.; Diana, P.; Parrino, B. New 1,2,4-Oxadiazole Nortopsentin Derivatives with Cytotoxic Activity. Mar. Drugs 2019, 17, 35.
    29. Tu, G.; Yan, Y.; Chen, X.; Lv, Q.; Wang, J.; Li, S. Synthesis and antiproliferative assay of 1,3,4-oxadiazole and 1,2,4-triazole derivatives in cancer cells. Drug Discov. Ther. 2013, 7, 58–65.
    30. Prasanna Kumar, B.N.; Mohana, K.N.; Mallesha, L.; Veeresh, B. Synthesis and in vitro antiproliferative activity of 2,5-disubstituted-1,3,4-oxadiazoles containing trifluoromethyl benzenesulfonamide moiety. Med. Chem. Res. 2014, 23, 3363–3373.
    31. Zhao, C.; Rakesh, K.P.; Ravidar, L.; Fang, W.Y.; Qin, H.L. Pharmaceutical and medicinal significance of sulfur (S(VI))-Containing motifs for drug discovery: A critical review. Eur. J. Med. Chem. 2019, 162, 679–734.
    32. Ertl, P.; Altmann, E.; McKenna, J.M. The Most Common Functional Groups in Bioactive Molecules and How Their Popularity Has Evolved over Time. J. Med. Chem. 2020, 63, 8408–8418.
    33. Bacharaju, K.; Jambula, S.R.; Sivan, S.; JyostnaTangeda, S.; Manga, V. Design, synthesis, molecular docking and biological evaluation of new dithiocarbamates substituted benzimidazole and chalcones as possible chemotherapeutic agents. Bioorganic Med. Chem. Lett. 2012, 22, 3274–3277.
    34. Li, Y.-B.; Yan, X.; Li, R.-D.; Liu, P.; Sun, S.-Q.; Wang, X.; Cui, J.-R.; Zhou, D.-M.; Ge, Z.-M.; Li, R.-T. Discovery of novel heteroarylmethylcarbamodithioates as potent anticancer agents: Synthesis, structure-activity relationship analysis and biological evaluation. Eur. J. Med. Chem. 2016, 112, 217–230.
    35. Weaver, B.A. How Taxol/paclitaxel kills cancer cells. Mol. Biol. Cell 2014, 25, 2677–2681.
    36. Avanzo, R.E.; Padrón, J.M.; D’Accorso, N.B.; Fascio, M.L. Synthesis and in vitro antiproliferative activities of (5-aryl-1,2,4-oxadiazole-3-yl) methyl d-ribofuranosides. Bioorganic Med. Chem. Lett. 2017, 27, 3674–3677.
    37. Jóźwiak, M.; Filipowska, A.; Fiorino, F.; Struga, M. Anticancer activities of fatty acids and their heterocyclic derivatives. Eur. J. Pharmacol. 2020, 871, 172937.
    38. Hassan, M.F.; Rauf, A.; Sherwani, A.; Owais, M. Synthesis and In Vitro Biological Evaluation of 1,3,4-Oxadiazol-2(3H)-one and Tetrahydropyridazine-3,6-dione Derivatives of Fatty Acids. Sci. Pharm. 2015, 83, 429–443.
    More